Bin Chen

Bin Chen has a diverse work experience in the pharmaceutical and biotechnology industry. Bin is currently the Vice President of Medicinal Chemistry at XtalPi Inc., where they utilize their expertise in quantum mechanics, artificial intelligence, and cloud computing to develop innovative drug discovery technologies. Prior to XtalPi, Bin Chen served as the Vice President of Medicinal Chemistry and BD Director at Shanghai Affinity Biopharmaceutical Co., Ltd, focusing on the development of Tumor MicroEnvironment Activated (TMEA) drugs. Bin also has experience as the Head of R&D API Division/BD US at Yabao Pharmaceutical Group Co., Ltd., where they managed a team and led the development of API products and key chemical intermediates. Bin Chen has held senior positions at WuXi AppTec China and Bristol-Myers Squibb, where they contributed to the development of small molecule drugs for various therapeutic areas. Bin began their career as a Postdoctoral Fellow at the Massachusetts Institute of Technology (MIT), conducting research in stereoselective reactions and biomimetic total synthesis.

Bin Chen completed a Bachelor of Science (B.Sc.) Honors degree in Chemistry at the University of Technology Sydney from 1995 to 1998. Later on, from 1999 to 2005, Bin Chen pursued a higher level of education and obtained a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Michigan.